Uterine fibroids: NICE recommends new treatment option for moderate to severe symptoms

The National Institute for Health and Care Excellence has recommended linzagolix (marketed as Yselty) for moderate to severe symptoms of uterine fibroids, an option that could benefit up to 30 000 adults in England and Wales.1In final guidance, published on 14 August, NICE said that linzagolix can be offered to adults of reproductive age for longer term treatment (at least six months) and can be taken with or without hormonal add-back therapy. It did not recommend the drug for people needing short term treatment, such as before planned surgery, as it was not clear whether this would be cost effective.Two in three women develop at least one uterine fibroid during their lifetime, with half of those developing symptoms. Moderate to severe symptoms, including pain, difficulty in conceiving and heavy menstrual bleeding, can negatively affect quality of life.Linzagolix is a gonadotropin releasing hormone (GnRH) antagonist that is administered as a once…
Read Original Article: Uterine fibroids: NICE recommends new treatment option for moderate to severe symptoms »